Rebecca joined Neuren in 2023, bringing over 25 years of experience across modalities and indications in companies small to large, in pharmaceutical, biotechnology and venture studio & venture capital environments. Rebecca is well versed in several modalities from small and large molecule, gene & cell therapy, diagnostic/device across a variety of indications: immunology, transplant, cardiovascular and metabolic, ophthalmology, neurodegenerative and rare diseases (adult & pediatric). Prior to joining Neuren, Rebecca held senior leadership roles at MedImmune/AstraZeneca, REGENXBIO, Regio Biosciences and Bloom Sciences. While at MedImmune, Rebecca built the cardiovascular & metabolic clinical operations department to deliver on the early-stage biologics portfolio. Rebecca expanded her scope as Chief Operating Officer in start-up biotech company Regio, to build the company from the foundation to enable a sponsor transfer of a clinical stage asset.
